Critical Outcome Technologies Invited to Present at 16th International p53 Workshop in Sweden
13 Juin 2014 - 3:00PM
Marketwired
Critical Outcome Technologies Invited to Present at 16th
International p53 Workshop in Sweden
LONDON, ONTARIO--(Marketwired - Jun 13, 2014) - Critical Outcome
Technologies Inc. ("COTI" or the "Company") (TSX-VENTURE:COT), the
bioinformatics and accelerated drug discovery company, announced
today that its President and CEO, Dr. Wayne Danter, will be a
featured presenter at the 16th International p53 Workshop at the
Stockholm Waterfront Congress Centre in Sweden, which runs from
June 15-19, 2014. This annual conference brings together
world-renowned scientists to discuss novel, basic, transitional,
and clinical research in the area of cancer biology with a focus on
the p53 tumor suppressor gene.
Dr. Danter's presentation is scheduled for Monday, June 16 at
3:15 p.m. CEST, and will highlight the Company's lead cancer drug
candidate, COTI-2, as a novel small molecule activator of mutant
p53 protein for the treatment of susceptible cancers. While at the
conference, Dr. Danter will also be meeting with Professor Sir
David Lane, known for his joint discovery of the p53 tumor
suppressor protein in 1979.
"I look forward to discussing our extensive preclinical findings
regarding COTI-2 with Professor Lane and several other p53 thought
leaders and interested parties," said Dr. Danter. "COTI-2 has a
major mechanism of action that is dependent on p53 gene mutation
status in human cancer cells. We are convinced that it is only a
matter of time before the world recognizes the potentially
transformational impact of COTI-2 in the treatment of many cancers
where there is a p53 gene mutation present in afflicted
patients."
Following Dr. Danter's scheduled presentation, the Company will
upload his slides to SlideShare at
www.slideshare.net/CriticalOutcome.
About Critical Outcome
Technologies Inc.
COTI is a leading-edge bioinformatics company specializing in
accelerating the discovery and development of small molecules -
dramatically reducing the time and cost to bring new drugs to
market. COTI's proprietary artificial intelligence system,
CHEMSAS®, utilizes a series of predictive computer models to
identify compounds with a high probability of being successfully
developed from disease specific drug discovery through chemical
optimization and preclinical testing. These compounds are targeted
for a variety of diseases, particularly those for which current
treatments are either lacking or ineffective.
For more information, visit www.criticaloutcome.com.
Follow @CriticalOutcome on Twitter at
http://twitter.com/CriticalOutcome
Notice to
Readers
Information contained in this press release may contain certain
statements, which constitute "forward-looking statements" within
the meaning of the Securities Act (Ontario) and applicable
securities laws. For example, the statement "… it is only a matter
of time before the world recognizes the potentially
transformational impact of COTI-2 in the treatment of many cancers
where there is a p53 gene mutation present in afflicted patients."
is a forward-looking statement. Forward‐looking statements by their
nature are not guarantees of future performance and are based upon
management's current expectations, estimates, projections and
assumptions. COTI operates in a highly competitive environment that
involves significant risks and uncertainties, which could cause
actual results to differ materially from those anticipated in these
forward‐looking statements. Management of COTI considers the
assumptions on which these forward‐looking statements are based to
be reasonable, but as a result of the many risk factors, cautions
the reader that actual results could differ materially from those
expressed or implied in these forward-looking statements.
Information in this press release should be considered accurate
only as of the date of the release and may be superseded by more
recent information disclosed in later press releases, filings with
the securities regulatory authorities or otherwise.
Neither TSX
Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this
release.
Critical Outcome Technologies Inc.Dr. Wayne DanterPresident
& CEO519-858-5157wdanter@criticaloutcome.comHeisler
CommunicationsTrevor HeislerInvestor
Relations416-500-8061trevor@heislercommunications.com
Cotinga Pharmaceuticals (TSXV:COT)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Cotinga Pharmaceuticals (TSXV:COT)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024